Did risk stratification modify the incidence of PML in natalizumab-treated MS patients in France?

Affiliation auteurs!!!! Error affiliation !!!!
TitreDid risk stratification modify the incidence of PML in natalizumab-treated MS patients in France?
Type de publicationJournal Article
Year of Publication2018
AuteursVukusic S., Rollot F., Pique J., Casey R., Mathey G., Edan G., Brassat D., Ruet A., De Seze J., Zephir H., Maillart E., Lebrun-Frenay C., Derache N., Labauge P., Moreau T., Laplaud D., Berger E., Moisset X., Rico-Lamy A., Thouvenot E., Stankoff B., Heinzlef O., Bourre B., Al-Kedhr A., Bensa C., Cabre P., Montcuquet A., Vaillant M., Camdessanche J.-P, Guennoc A.-M, Wahab A., Maubeuge N., Labeyrie C., Patry I., Nifle C., Hankiewicz K., Tourbah A., Investigators OFSEP
JournalMULTIPLE SCLEROSIS JOURNAL
Volume24
Pagination993-994
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN1352-4585